Clinical and psychological profile and quality of life of patients with post-shoe syndrome

Authors:
L.V. Chichanovskaya, T.A. Slyusar, Yu.V. Abramenko, T.M. Nekrasova, I.N. Slyusar

FSBEI in the Tver State Medical University of the Ministry of Health of Russia, Tver, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 4

Summary:
Purpose of the study. To study the clinical and psychological profile and the quality of life of patients with post-shoe syndrome (PKS). Material and methods. 162 patients aged 24-60 years with a confirmed coronary reerovirus infection caused by the SARS-COV-2 virus, having symptoms that were the basis for the diagnosis of PKS, were examined. Patients underwent a neurological and general somatic examination with the identification of the corresponding neurological syndromes. They evaluated the intensity and nature of the pain (Mc Gill questionnaire), the level of psychosocial stress (Holmes-Road questionnaire), the severity of asthenia (the MFI-20 scale), the level of anxiety (Spielberger-Khanin questionnaire), depression (Bek scale). The quality of life was carried out by applying the Russian version of the SF-36 questionnaire. To correct the identified disorders, Mexidol was used 500 mg once a day every day in/in drip for 14 days, followed by the Mexidol Fort 250, 1 tablet 3 times a day for 2 months. Results . The course of treatment with Mexidol of patients with a PKS led to a decrease in the severity of subjective and objective symptoms of the PKS, asthenic, anxious and depressed disorders, and improved the quality of life of patients. Conclusion. The high efficiency and safety of consistent therapy with Mexidol (V/V, then orally Mexidol Forte 250) in patients with PKS are shown. Key words: post-shoe syndrome, coronavirus infection SARS-COV-2, emotional disorders, anxiety, depression, quality of life, Mexidol.